Clearside Biomedical Inc (CLSD) - News Archive

In the realm of ophthalmology, the continual quest for innovative treatments to address macular diseases has garnered significant attention, and Clearside Biomedical Inc. stands at the forefront of this endeavour. At th...

The article discusses the noteworthy contributions of Clearside Biomedical in the field of retinal drug development, as presented by Dr. Victor Chong at the Edridge Green Lecture. The subsequent publication of these ins...

Clearside Biomedical has recently reported the completion of the final participant visit in its ODYSSEY Phase 2b trial for CLS-AX in the treatment of neovascular age-related macular degeneration (wet AMD). Highlighting...

Clearside Biomedical and its partner Arctic Vision have announced promising results from their Phase 3 clinical trial of ARCATUS, a novel therapy designed for suprachoroidal use in treating uveitic macular edema. This b...

Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company specializing in delivering therapies to the back of the eye through the suprachoroidal space (SCS), has announced the appointment of Glenn C. Yiu, M...

Clearside Biomedical, a leading biopharmaceutical company specializing in the development of innovative therapies to treat sight-threatening eye diseases, is set to host a virtual Key Opinion Leader (KOL) event on the u...

Clearside Biomedicals Leadership in Suprachoroidal Delivery Featured in Multiple Presentations at the Clinical Trials at the Summit Meeting- Broad Use of Suprachoroidal Injection Platform Highlighted Across Retinal Indi...

Clearside Biomedical Announces Publication of Consensus Guidelines for Optimizing Retinal Therapeutic Delivery via Suprachoroidal Space (SCS) Injection in Industry-Leading Journal, RETINA- Expert Ophthalmologists Unveil...

Clearside Biomedical Inc, a biopharmaceutical company specializing in retinal disease research and clinical development, recently announced the appointment of Victor Chong, M.D., MBA as their Chief Medical Officer. Dr....